ClinicalTrials.gg
TerminatedNCT04338022Updated Jun 12, 2025Results posted

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

A Phase 3 interventional study of Teriflunomide and Evobrutinib in Relapsing Multiple Sclerosis, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Terminated at 279 sites in 31 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary analysis of the RMS phase 3 study (MS200527_0080) resulted in the early termination of the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,124
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.

Enrollment
2nd of 33
1,124 · median 219
Started
2020
with 1 other
Phase 3
11 of 71
none open now
Registered
63rd of 71
by date

Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 3, and was the 63rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Evobrutinib
  • Teriflunomide
  • Aubagio®
  • Relapsing Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
  • Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
  • Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score \<= 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
  • Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
  • Female participants must be neither pregnant nor breast-feeding or must lack (as defined by either: or surgically sterile), or use an effective method of for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Participants have given written prior to any study-related procedure
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b).

Participants with secondary progressive MS without evidence of relapse

  • Disease duration more than (>) 10 years in participants with an EDSS =\< 2.0 at screening and Baseline (Day 1)
  • Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,124 participants (actual)

Study arms

  • Active comparator
    Teriflunomide

    Drug: Teriflunomide

  • Experimental
    Evobrutinib

    Drug: Evobrutinib

Interventions

  • Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.

  • Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.

    Also known as: M2951

06

What researchers measure

Primary outcomes

  1. Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)

    The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs,) and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

    Time frame: From baseline to 172 weeks

  2. Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEs

    Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.

    Time frame: From OLE Baseline (DBTP Week 96) to OLE Week 52

Secondary outcomes

  1. DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE period)

  2. DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)

  3. DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

    Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.

    Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)

  4. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)

  5. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)

  6. DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions

    Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.

    Time frame: From baseline to 176 weeks

  7. DBTP and DBE Period: New or Enlarging T2 Lesions Rate

    Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.

    Time frame: From baseline to 176 weeks

  8. DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12

    NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.

    Time frame: Week 12

  9. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

    Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.

    Time frame: From baseline to 176 weeks

  10. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

    Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.

    Time frame: From baseline to 176 weeks

  11. DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

    Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  12. DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate

    Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  13. DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate

    Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  14. DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight

    Changes in vital signs: weight from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  15. DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature

    Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  16. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate

    Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: heart rate from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  17. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameters: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration

    QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  18. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  19. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  20. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  21. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  22. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  23. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  24. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  25. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  26. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 176 weeks were reported.

    Time frame: From baseline to 176 weeks

  27. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 176 weeks was reported. The Glomerular Filtration Rate will be measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).

    Time frame: From baseline to 176 weeks

  28. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  29. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 176 weeks was reported.

    Time frame: From baseline to 176 weeks

  30. DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels

    Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.

    Time frame: At Week 176

  31. DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels

    Change from baseline serum levels of IgG, IgA, IgM were assessed.

    Time frame: Baseline to 176 weeks

  32. OLE Period: Annualized Relapse Rate (ARR)

    The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, AEs, and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  33. OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  34. OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

    Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  35. OLE Period: Symbol Digit Modalities Test (SDMT)

    The SDMT is a test of information processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a "key", showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110 where higher scores indicated improvement and lower scores indicated worsening. Participant wise data was reported for this outcome measure.

    Time frame: Assessed from OLE baseline to OLE Week 96; OLE Week 48 were reported for Participants 1 and 2 and OLE Week 12 were reported for Participant 3

  36. OLE Period: Change From Baseline in PROMISnq Physical Function (PF) Multiple Sclerosis (MS) 15a at Week 52

    Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and ranges from 10 to 65. Higher T-scores represent higher physical function. Participant wise data was reported for this outcome measure.

    Time frame: OLE Baseline (DBTP Week 96), OLE Week 52

  37. OLE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue (MS) 8a Score at Week 52

    PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In general, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Participant wise data was reported for this outcome measure.

    Time frame: OLE baseline (DBTP Week 96), OLE Week 52

  38. OLE Period: Number of Participants With Abnormalities in Laboratory Parameters

    Laboratory investigation included hematology, biochemistry and coagulation. The number of participants with abnormalities in laboratory parameters were reported.

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  39. OLE Period: Number of Participants With Abnormalities in Vital Signs

    Vital signs included temperature, pulse rate, respiration rate and blood pressure and weight (taken after 5 minutes in the sitting position). The number of participants with abnormalities in vital signs were reported.

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  40. OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings

    ECG recordings included, heart rate, PR interval and QRS duration. ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The number of participants with abnormalities in ECG findings were reported.

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  41. OLE Period: Number of New or Enlarging T2 Lesions

    Analysis of number of new or enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan. Participant wise data was reported for this outcome measure.

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

  42. OLE Period: Change From Baseline in T2 Lesion Volume

    Change from baseline in T2 lesion volume was reported. Participant wise data was reported for this outcome measure.

    Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52

07

Results

Posted Jun 12, 2025
Limitations and caveats
The Final Analysis represents the analysis of the cumulative data collected up to the Primary Analysis trigger and beyond through DBE up to the final database lock. Therefore, the endpoints were evaluated considering a time period from the start of DBTP to the end of the DBE Period.

Participant flow

Double-blind Treatment Period: 156 Weeks
Participant flow — Double-blind Treatment Period: 156 Weeks
MilestoneTeriflunomideEvobrutinib
Started564560
Completed396384
Not completed168176
Withdrew: Adverse event5672
Withdrew: Lost to follow-up65
Withdrew: Lack of efficacy1923
Withdrew: Withdrawal by subject5655
Withdrew: Death11
Withdrew: Protocol non-compliance55
Withdrew: Other reason2414
Withdrew: Randomized, but not treated11
Double-blind Extension: 96 Weeks
Participant flow — Double-blind Extension: 96 Weeks
MilestoneTeriflunomideEvobrutinib
Started377359
Completed371346
Not completed613
Withdrew: Lack of efficacy12
Withdrew: Withdrawal by subject01
Withdrew: Adverse event20
Withdrew: Lost to follow-up01
Withdrew: Other reason39
Open Label Extension: 96 Weeks
Participant flow — Open Label Extension: 96 Weeks
MilestoneTeriflunomideEvobrutinib
Started03
Completed00
Not completed03
Withdrew: Study termination03

Outcome measures

PrimaryDouble Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)

The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs,) and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

Time frame:
From baseline to 172 weeks
Reported as:
Mean · relapses per year
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)
relapses per yearTeriflunomideEvobrutinib
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)0.13 (0.11 to 0.15)0.14 (0.12 to 0.16)
PrimaryOpen Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEs

Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.

Time frame:
From OLE Baseline (DBTP Week 96) to OLE Week 52
Reported as:
Count of participants · Participants
Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEs
ParticipantsEvobrutinib
Participants with AEs1
Participants with Serious AEs0
SecondaryDBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE period)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 9691.0 (88.0 to 93.3)91.3 (88.3 to 93.5)
Week 15686.0 (81.5 to 89.5)87.9 (83.5 to 91.1)
SecondaryDBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE periods)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 9694.3 (91.9 to 96.1)92.7 (89.9 to 94.7)
Week 15692.3 (89.2 to 94.5)92.1 (89.2 to 94.3)
SecondaryDBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.

Time frame:
Week 96 and Week 156 (combined DBTP and DBE periods)
Reported as:
Number · percentage of participants
DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsTeriflunomideEvobrutinib
Week 967.9 (5.6 to 11.2)9.4 (6.7 to 13.0)
Week 1568.8 (6.2 to 12.4)10.1 (7.3 to 13.9)
SecondaryDBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156

Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

Time frame:
Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)
Reported as:
Least squares mean · units on a scale
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156
units on a scaleTeriflunomideEvobrutinib
Week 48-0.30 (-0.79 to 0.19)0.05 (-0.45 to 0.55)
Week 96-0.76 (-1.35 to -0.16)-0.14 (-0.74 to 0.46)
Week 120-0.29 (-0.95 to 0.37)-0.25 (-0.92 to 0.42)
Week 144-1.04 (-1.82 to -0.25)-0.70 (-1.53 to 0.14)
Week 156-1.61 (-2.70 to -0.51)-1.44 (-2.66 to -0.23)
SecondaryDBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156

PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

Time frame:
Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)
Reported as:
Least squares mean · units on a scale
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156
units on a scaleTeriflunomideEvobrutinib
Week 48-1.39 (-1.98 to -0.81)-1.82 (-2.41 to -1.23)
Week 96-1.60 (-2.32 to -0.87)-2.14 (-2.88 to -1.41)
Week 120-1.44 (-2.25 to -0.63)-1.32 (-2.15 to -0.50)
Week 144-1.88 (-2.90 to -0.86)-0.98 (-2.06 to 0.10)
Week 1560.72 (-0.78 to 2.22)-0.21 (-1.90 to 1.48)
SecondaryDBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions

Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · lesions per scan
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions
lesions per scanTeriflunomideEvobrutinib
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions0.35 (0.29 to 0.42)0.52 (0.43 to 0.62)
SecondaryDBTP and DBE Period: New or Enlarging T2 Lesions Rate

Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · lesions per year
DBTP and DBE Period: New or Enlarging T2 Lesions Rate
lesions per yearTeriflunomideEvobrutinib
DBTP and DBE Period: New or Enlarging T2 Lesions Rate5.78 (5.02 to 6.65)5.45 (4.73 to 6.28)
SecondaryDBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12

NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.

Time frame:
Week 12
Reported as:
Geometric mean · nanogram per liter (ng/L)
DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12
nanogram per liter (ng/L)TeriflunomideEvobrutinib
DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 1212.90 (12.48 to 13.34)12.88 (12.46 to 13.31)
SecondaryDBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.

Time frame:
From baseline to 176 weeks
Reported as:
Count of participants · Participants
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsTeriflunomideEvobrutinib
Participants with TEAEs485482
Participants with AESIs120117
SecondaryDBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Count of participants · Participants
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
ParticipantsTeriflunomideEvobrutinib
Participants with Grade 15056
Participants with Grade 2349327
Participants with Grade 38288
Participants with Grade 4310
Participants with Grade 511
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · millimeter of mercury (mmHg)
DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
millimeter of mercury (mmHg)TeriflunomideEvobrutinib
Systolic Blood Pressure2.6 ± 11.180.2 ± 10.83
Diastolic Blood Pressure1.8 ± 8.350.0 ± 8.67
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate

Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · beats per minute
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate
beats per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate2.6 ± 10.221.9 ± 9.68
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate

Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · breaths per minute
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate
breaths per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate-0.1 ± 1.76-0.2 ± 1.88
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Weight

Changes in vital signs: weight from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · kilograms (kg)
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight
kilograms (kg)TeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight-0.21 ± 5.8670.48 ± 5.490
SecondaryDBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature

Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · degree Celsius
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature
degree CelsiusTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature0.00 ± 0.3260.02 ± 0.319
SecondaryDBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate

Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: heart rate from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · beats per minute
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate
beats per minuteTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate3.0 ± 10.90-0.1 ± 12.55
SecondaryDBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameters: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration

QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · milliseconds (msec)
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameters: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration
milliseconds (msec)TeriflunomideEvobrutinib
QT Interval - Fridericia's Correction Formula-2.77 ± 16.005-1.37 ± 12.053
PR Interval-5.2 ± 14.31-2.5 ± 14.65
QRS Duration-3.7 ± 7.48-1.5 ± 10.82
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
gram per liter (g/L)TeriflunomideEvobrutinib
Hemoglobin-3.5 ± 10.74-2.8 ± 11.34
Erythrocytes Mean Corpuscular HGB Concentration-2.7 ± 12.43-1.0 ± 11.96
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · 10^9 cells per liter
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes
10^9 cells per literTeriflunomideEvobrutinib
Platelets-4.8 ± 47.098.8 ± 53.83
Leukocytes-0.17 ± 2.165-0.09 ± 1.958
Neutrophils-0.316 ± 1.8846-0.210 ± 1.8356
Eosinophils0.0510 ± 0.159990.0203 ± 0.15853
Basophils-0.0009 ± 0.03657-0.0003 ± 0.03786
Monocytes0.0785 ± 0.181710.0656 ± 0.17816
Lymphocytes-0.0307 ± 0.58566-0.0401 ± 0.58108
Reticulocytes0.488 ± 20.2014-0.827 ± 17.6824
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · percentage of cells
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit
percentage of cellsTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit-0.0069 ± 0.03359-0.0076 ± 0.03238
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · picogram (pg)
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
picogram (pg)TeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin-0.61 ± 1.588-0.62 ± 1.956
SecondaryDBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · femtoliters
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
femtolitersTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume-1.42 ± 5.999-1.75 ± 4.895
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · micromoles per liter (mcmol/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine
micromoles per liter (mcmol/L)TeriflunomideEvobrutinib
Bilirubin-0.08 ± 4.7920.15 ± 4.792
Creatinine0.6 ± 12.762.4 ± 8.67
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · units per liter (U/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase
units per liter (U/L)TeriflunomideEvobrutinib
Aspartate Aminotransferase2.32 ± 18.1906.49 ± 64.249
Alanine Aminotransferase4.06 ± 23.3088.55 ± 52.866
Alkaline Phosphatase4.20 ± 23.2897.65 ± 20.252
Amylase-0.5 ± 17.042.8 ± 16.84
Lipase-2.5 ± 33.363.5 ± 17.33
Gamma Glutamyl Transferase4.28 ± 21.0915.51 ± 40.098
Lactate Dehydrogenase6.16 ± 28.235-4.53 ± 26.014
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · millimole per liter (mmol/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium
millimole per liter (mmol/L)TeriflunomideEvobrutinib
Sodium0.9128 ± 2.343340.7904 ± 2.28990
Potassium0.0320 ± 0.437410.0893 ± 0.42341
Calcium0.004 ± 0.1139-0.002 ± 0.1029
Magnesium0.004 ± 0.06820.002 ± 0.0656
Glucose0.06 ± 0.9280.25 ± 1.146
Chloride1.8 ± 3.421.7 ± 2.95
Urea Nitrogen0.222 ± 1.26680.114 ± 1.2654
Phosphate-0.053 ± 0.2048-0.026 ± 0.1724
Bicarbonate0.05 ± 2.5610.04 ± 2.725
Corrected Calcium0.0297 ± 0.094280.0317 ± 0.09071
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 176 weeks were reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin
gram per liter (g/L)TeriflunomideEvobrutinib
Total protein-1.26 ± 4.865-0.47 ± 4.417
Albumin-1.28 ± 3.520-1.67 ± 3.284
SecondaryDBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate

Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 176 weeks was reported. The Glomerular Filtration Rate will be measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).

Time frame:
From baseline to 176 weeks
Reported as:
Mean · mL/min/1.73m^2
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate
mL/min/1.73m^2TeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate-3.3 ± 13.82-5.6 ± 13.54
SecondaryDBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine

Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · pH
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine
pHTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine-0.08 ± 0.8860.01 ± 0.913
SecondaryDBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine

Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 176 weeks was reported.

Time frame:
From baseline to 176 weeks
Reported as:
Mean · Kilogram per cubic meter
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine
Kilogram per cubic meterTeriflunomideEvobrutinib
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine0.0006 ± 0.038910.0011 ± 0.02189
SecondaryDBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels

Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.

Time frame:
At Week 176
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels
gram per liter (g/L)TeriflunomideEvobrutinib
IgA1.750 ± 0.79872.503 ± 1.0582
IgG9.693 ± 2.109610.529 ± 2.2363
IgM1.101 ± 0.60961.181 ± 0.6619
SecondaryDBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels

Change from baseline serum levels of IgG, IgA, IgM were assessed.

Time frame:
Baseline to 176 weeks
Reported as:
Mean · gram per liter (g/L)
DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels
gram per liter (g/L)TeriflunomideEvobrutinib
IgA-0.262 ± 0.35720.483 ± 0.5320
IgG-0.733 ± 1.44140.105 ± 1.4556
IgM-0.165 ± 0.2979-0.187 ± 0.2794
SecondaryOLE Period: Annualized Relapse Rate (ARR)

The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, AEs, and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Mean · relapses per year
OLE Period: Annualized Relapse Rate (ARR)
relapses per yearEvobrutinib
OLE Period: Annualized Relapse Rate (ARR)NA (NA to NA)
SecondaryOLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Number · percentage of participants
OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsEvobrutinib
OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)0
SecondaryOLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Number · percentage of participants
OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
percentage of participantsEvobrutinib
OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)0
SecondaryOLE Period: Symbol Digit Modalities Test (SDMT)

The SDMT is a test of information processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a "key", showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110 where higher scores indicated improvement and lower scores indicated worsening. Participant wise data was reported for this outcome measure.

Time frame:
Assessed from OLE baseline to OLE Week 96; OLE Week 48 were reported for Participants 1 and 2 and OLE Week 12 were reported for Participant 3
Reported as:
Number · units on a scale
OLE Period: Symbol Digit Modalities Test (SDMT)
units on a scaleEvobrutinib
Participant 160
Participant 240
Participant 350
SecondaryOLE Period: Change From Baseline in PROMISnq Physical Function (PF) Multiple Sclerosis (MS) 15a at Week 52

Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and ranges from 10 to 65. Higher T-scores represent higher physical function. Participant wise data was reported for this outcome measure.

Time frame:
OLE Baseline (DBTP Week 96), OLE Week 52
Reported as:
Number · T-score
OLE Period: Change From Baseline in PROMISnq Physical Function (PF) Multiple Sclerosis (MS) 15a at Week 52
T-scoreEvobrutinib
Participant 152
Participant 263
Participant 351
SecondaryOLE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue (MS) 8a Score at Week 52

PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In general, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Participant wise data was reported for this outcome measure.

Time frame:
OLE baseline (DBTP Week 96), OLE Week 52
Reported as:
Number · T-score
OLE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue (MS) 8a Score at Week 52
T-scoreEvobrutinib
Participant 143
Participant 242
Participant 341
SecondaryOLE Period: Number of Participants With Abnormalities in Laboratory Parameters

Laboratory investigation included hematology, biochemistry and coagulation. The number of participants with abnormalities in laboratory parameters were reported.

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Abnormalities in Laboratory Parameters
ParticipantsEvobrutinib
Hematology1
Biochemistry1
Coagulation0
SecondaryOLE Period: Number of Participants With Abnormalities in Vital Signs

Vital signs included temperature, pulse rate, respiration rate and blood pressure and weight (taken after 5 minutes in the sitting position). The number of participants with abnormalities in vital signs were reported.

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Abnormalities in Vital Signs
ParticipantsEvobrutinib
OLE Period: Number of Participants With Abnormalities in Vital Signs0
SecondaryOLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings

ECG recordings included, heart rate, PR interval and QRS duration. ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The number of participants with abnormalities in ECG findings were reported.

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings
ParticipantsEvobrutinib
OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings1
SecondaryOLE Period: Number of New or Enlarging T2 Lesions

Analysis of number of new or enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan. Participant wise data was reported for this outcome measure.

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Number · number of lesions
OLE Period: Number of New or Enlarging T2 Lesions
number of lesionsEvobrutinib
Participant 111
Participant 20
Participant 30
SecondaryOLE Period: Change From Baseline in T2 Lesion Volume

Change from baseline in T2 lesion volume was reported. Participant wise data was reported for this outcome measure.

Time frame:
From OLE baseline (DBTP Week 96) to OLE Week 52
Reported as:
Number · milliliter (mL)
OLE Period: Change From Baseline in T2 Lesion Volume
milliliter (mL)Evobrutinib
Participant 10.471
Participant 2-0.111
Participant 30

Adverse events

Collected over From baseline to 176 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teriflunomide1/563 (0.2%)33/563 (5.9%)409/563 (72.6%)
Evobrutinib1/559 (0.2%)45/559 (8.1%)361/559 (64.6%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventTeriflunomideEvobrutinib
Multiple sclerosis relapseNervous system disorders3/5634/559
COVID-19 pneumoniaInfections and infestations4/5633/559
COVID-19Infections and infestations0/5633/559
Femoral neck fractureInjury, poisoning and procedural complications0/5632/559
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5632/559
Abnormal uterine bleedingReproductive system and breast disorders0/5632/559
CellulitisInfections and infestations2/5631/559
PneumoniaInfections and infestations2/5631/559
Iron deficiency anaemiaBlood and lymphatic system disorders0/5631/559
ThrombocytopeniaBlood and lymphatic system disorders0/5631/559
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTeriflunomideEvobrutinib
COVID-19Infections and infestations108/563121/559
Alanine aminotransferase increasedInvestigations86/56377/559
HeadacheNervous system disorders75/56381/559
NasopharyngitisInfections and infestations61/56367/559
AlopeciaSkin and subcutaneous tissue disorders59/56332/559
Aspartate aminotransferase increasedInvestigations54/56351/559
DiarrhoeaGastrointestinal disorders53/56315/559
Neutrophil count decreasedInvestigations50/56325/559
Upper respiratory tract infectionInfections and infestations42/56336/559
NeutropeniaBlood and lymphatic system disorders41/56320/559

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(Years)TeriflunomideEvobrutinibTotal
Mean38 ± 9.537 ± 9.638 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)TeriflunomideEvobrutinibTotal
Female374377751
Male190183373
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TeriflunomideEvobrutinibTotal
Ethnicity-Hispanic or Latino6063123
Ethnicity-Not Hispanic or Latino5044971001
Race-American Indian or Alaska Native61319
Race-Asian101626
Race-Black or African American246
Race-Multiple527
Race-Other213
Race-Unknown or Not Reported358
Race-White5365191055
08

Study locations

279 sites
  • Research Site 629
    Mobile, Alabama 36693-7003, United States
  • Research Site 614
    Phoenix, Arizona 85013, United States
  • Research Site 677
    Phoenix, Arizona 85018, United States
  • Research Site 642
    Long Beach, California 90806, United States
  • Research Site 644
    Pasadena, California 91105, United States
  • Research Site 672
    San Diego, California 92121, United States
  • Research Site 634
    Stamford, Connecticut 06905, United States
  • Research Site 656
    Washington, District of Columbia 20007, United States
  • Research Site 616
    Boca Raton, Florida 33428, United States
  • Research Site 625
    Maitland, Florida 32751, United States
  • Research Site 617
    Miami, Florida 33136, United States
  • Research Site 643
    Ormond Beach, Florida 32174, United States
  • Research site 645
    Saint Petersburg, Florida 33713, United States
  • Research Site 652
    Tallahassee, Florida 32308, United States
  • Research Site 621
    Elk Grove Village, Illinois 60007, United States
  • Research Site 649
    Northbrook, Illinois 60062, United States
  • Research Site 675
    Peoria, Illinois 61637, United States
  • Research Site 628
    Rolling Meadows, Illinois 60008, United States
  • Research Site 624
    Indianapolis, Indiana 46256, United States
  • Research Site 632
    Kansas City, Kansas 66160, United States
  • Research Site 653
    New Orleans, Louisiana 70115, United States
  • Research Site 623
    Baltimore, Maryland 21201, United States
  • Research Site 633
    Boston, Massachusetts 02114, United States
  • Research Site 639
    Foxboro, Massachusetts 02035, United States
  • Research Site 635
    Lawrence, Massachusetts 01843, United States
  • Research Site 636
    Worcester, Massachusetts 01655, United States
  • Research Site 613
    Detroit, Michigan 48201, United States
  • Research Site 612
    Farmington Hills, Michigan 48334, United States
  • Research Site 638
    Saint Louis, Missouri 63110, United States
  • Research Site 664
    Saint Louis, Missouri 63131, United States
  • Research Site 668
    Omaha, Nebraska 68130, United States
  • Research Site 626
    Las Vegas, Nevada 89106, United States
  • Research Site 667
    Audubon, New Jersey 08106, United States
  • Research Site 620
    Patchogue, New York 11772, United States
  • Research Site 663
    Akron, Ohio 44320, United States
  • Research Site 630
    Toledo, Ohio 43614-2598, United States
  • Research Site 611
    Oklahoma City, Oklahoma 73104, United States
  • Research Site 641
    Oklahoma City, Oklahoma 73104, United States
  • Research Site 615
    Springfield, Oregon 97477, United States
  • Research Site 647
    Willow Grove, Pennsylvania 19090, United States
  • Research Site 648
    Knoxville, Tennessee 37922, United States
  • Research Site 627
    Nashville, Tennessee 37205, United States
  • Research Site 637
    Nashville, Tennessee 37215, United States
  • Research Site 662
    Dallas, Texas 75214, United States
  • Research Site 631
    Houston, Texas 77030, United States
  • Research Site 650
    Lubbock, Texas 79410, United States
  • Research Site 619
    Round Rock, Texas 78681, United States
  • Research Site 676
    Layton, Utah 84041, United States
  • Research Site 673
    Alexandria, Virginia 22310, United States
  • Research Site 654
    Virginia Beach, Virginia 23456, United States
  • Research Site 651
    Milwaukee, Wisconsin 53226-3596, United States
  • Research Site 566
    Ciudad Autonoma Buenos Aires, Argentina
  • Research Site 567
    Ciudad Autonoma Buenos Aires, Argentina
  • Research Site 574
    Ciudad Autonoma Buenos Aires, Argentina
  • Research Site 579
    Ciudad Autonoma Buenos Aires, Argentina
  • Research Site 561
    Ciudad Autonoma de Buenos Aires, Argentina
  • Research Site 562
    Ciudad Autonoma de Buenos Aires, Argentina
  • Research Site 577
    Ciudad Autonoma de Buenos Aires, Argentina
  • Research Site 564
    Cordoba, Argentina
  • Research Site 568
    Godoy Cruz, Argentina
  • Research Site 576
    Guaymallen, Argentina
  • Research Site 565
    Rosario, Argentina
  • Research Site 569
    Rosario, Argentina
  • Research Site 571
    Salta, Argentina
  • Research Site 572
    San Juan, Argentina
  • Research Site 563
    San Miguel de Tucuman, Argentina
  • Research Site 104
    Auchenflower, Australia
  • Research Site 107
    Concord, Australia
  • Research Site 109
    Hobart, Australia
  • Research Site 101
    Liverpool, Australia
  • Research Site 102
    New Lambton Heights, Australia
  • Research Site 103
    St Leonards, Australia
  • Research Site 151
    Innsbruck, Austria
  • Research Site 156
    Linz, Austria
  • Research Site 154
    Salzburg, Austria
  • Research Site 153
    Vienna, Austria
  • Research Site 474
    Bruxelles, Belgium
  • Research Site 475
    Bruxelles, Belgium
  • Research Site 473
    Kortrijk, Belgium
  • Research Site 471
    La Louvière, Belgium
  • Research Site 472
    Liège, Belgium
  • Research Site 478
    Overpelt, Belgium
  • Research Site 476
    Roeselare, Belgium
  • Research Site 161
    Bihac, Bosnia and Herzegovina
  • Research Site 163
    Mostar, Bosnia and Herzegovina
  • Research Site 162
    Sarajevo, Bosnia and Herzegovina
  • Research Site 171
    Pleven, Bulgaria
  • Research Site 174
    Pleven, Bulgaria
  • Reasearch Site 175
    Plovdiv, Bulgaria
  • Research Site 177
    Plovdiv, Bulgaria
  • Research Site 172
    Sofia, Bulgaria
  • Research Site 173
    Sofia, Bulgaria
  • Research Site 176
    Sofia, Bulgaria
  • Research Site 178
    Sofia, Bulgaria
  • Research Site 179
    Sofia, Bulgaria
  • Research Site 180
    Sofia, Bulgaria
  • Research Site 126
    Greenfield Park, Canada
  • Research Site 125
    Levis, Canada
  • Research Site 128
    Moncton, Canada
  • Research Site 129
    Montreal, Canada

Showing the first 100 of 279 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. PubMed 39307151 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union

Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.

Data sharing details ↗ · bit.ly

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Oct 2023, 39 months.

Results were first posted in Jun 2025, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2020
First posted
Apr 8, 2020
StartActual
Jun 12, 2020
Primary completionActual
Oct 2, 2023
CompletionActual
Mar 8, 2024
Results first posted
Jun 12, 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04338022
Responsible party
Sponsor
First posted
Apr 8, 2020
Start date
Jun 12, 2020
Primary completion
Oct 2, 2023
Completion
Mar 8, 2024
Results posted
Jun 12, 2025
Last update
Jun 12, 2025

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion